4//SEC Filing
JANNEY DANIEL 4
Accession 0001711279-23-000046
CIK 0001711279other
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 7:03 PM ET
Size
20.4 KB
Accession
0001711279-23-000046
Insider Transaction Report
Form 4
JANNEY DANIEL
Director
Transactions
- Sale
Common Stock
2023-06-09$129.29/sh−3,935$508,773→ 122,362 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-09$128.53/sh−10,000$1,285,262→ 107,362 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-08$127.96/sh−4,604$589,118→ 152,758 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-08$129.02/sh−1,073$138,440→ 151,685 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-08$127.96/sh−5,000$639,790→ 141,297 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-08$127.86/sh−5,000$639,306→ 126,297 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-09$128.84/sh−5,000$644,188→ 117,362 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-08$128.73/sh−5,388$693,616→ 146,297 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.) - Sale
Common Stock
2023-06-08$127.96/sh−10,000$1,279,584→ 131,297 total(indirect: Directly beneficially owned by Alta Bioequities, L.P.)
Footnotes (7)
- [F1]Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- [F2]The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F6]The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F7]The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Documents
Issuer
Krystal Biotech, Inc.
CIK 0001711279
Entity typeother
Related Parties
1- filerCIK 0001198325
Filing Metadata
- Form type
- 4
- Filed
- Jun 8, 8:00 PM ET
- Accepted
- Jun 9, 7:03 PM ET
- Size
- 20.4 KB